RxDoctor Payments Data

Julie Williams

Physician Assistant · Round Rock, TXNPI 1952427007

Payments from drug & device makers

$10,010in general payments, 2019–2025

Across 511 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • AbbVie$929
  • Lundbeck LLC$814
  • Neurocrine Biosciences, Inc.$801
  • Alkermes, Inc.$657
  • plus $4K from 28 others

What the payments were for

  • Food & beverage$9,998100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,010 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$16,162
Medicare patients
55
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ziprasidone Hcl17$2,760
Vilazodone Hcl22$2,040
Clozapine30$2,027
Desvenlafaxine Succinate ErDesvenlafaxine Succinate21$1,812
Divalproex Sodium ErDivalproex Sodium19$1,513
Gabapentin56$1,005
Buspirone Hcl31$967
Duloxetine Hcl38$873
Quetiapine Fumarate67$867
Trazodone Hcl44$814
Lamotrigine48$652
Venlafaxine Hcl ErVenlafaxine Hcl15$645
Fluoxetine Hcl67$580
Oxcarbazepine18$513
Levetiracetam18$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$21$28716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →